Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation

Katherine Parker Ponder, Sanjeev Gupta, Frances Leland, Gretchen Darlington, Milton Finegold, Janet DeMayo, Fred D. Ledley, Jayanta Roy-Chowdhury, Savio L C Woo

Research output: Contribution to journalArticle

313 Citations (Scopus)

Abstract

One approach to gene therapy for hepatic diseases is to remove hepatocytes from an affected individual, genetically alter them in vitro, and reimplant them into a receptive locus. Although returning hepatocytes to the liver itself would be advantageous, the feasibility of this approach has never been evaluated due to the inability to distinguish donor from host hepatocytes. To unambiguously identify transplanted hepatocytes after transplantation, and to better quantitate their number and degree of liver function, two transgenic mouse lines were generated in a C57BL/6 background. The first expresses the Escherichia coli β-galactosidase gene from the relatively liver-specific human α1antitrypsin (hAAT) promoter and allows transgenic hepatocytes to be readily identified after 5-bromo-4-chloro-3-indolyl β-D-galactoside staining; the second produces the hAAT protein under control of the same promoter, which enables hepatocyte survival and maintenance of liver function to be quantitated by measuring the serum levels of hAAT. Hepatocytes isolated from transgenic donors were transplanted into nontransgenic C57BL/6 recipients by intrasplenic injection. Surprisingly, a large fraction of these cells were identified within the liver parenchyma but not the spleen at 2 months after transplantation. The high levels of serum hAAT detected in transplant recipients were stable for >6 months, suggesting that established cells will survive indefinitely. These results have important implications for liver organogenesis and hepatic gene therapy.

Original languageEnglish (US)
Pages (from-to)1217-1221
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume88
Issue number4
StatePublished - 1991

Fingerprint

Hepatocytes
Transplantation
Liver
Genetic Therapy
Tissue Donors
Galactosidases
Galactosides
Organogenesis
Serum
Transgenic Mice
Spleen
Maintenance
Staining and Labeling
Escherichia coli
Injections
Genes
Proteins

Keywords

  • α-antitrypsin
  • β-galactosidase
  • Gene therapy
  • Hepatocyte transplantation

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. / Ponder, Katherine Parker; Gupta, Sanjeev; Leland, Frances; Darlington, Gretchen; Finegold, Milton; DeMayo, Janet; Ledley, Fred D.; Roy-Chowdhury, Jayanta; Woo, Savio L C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, No. 4, 1991, p. 1217-1221.

Research output: Contribution to journalArticle

Ponder, Katherine Parker ; Gupta, Sanjeev ; Leland, Frances ; Darlington, Gretchen ; Finegold, Milton ; DeMayo, Janet ; Ledley, Fred D. ; Roy-Chowdhury, Jayanta ; Woo, Savio L C. / Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. In: Proceedings of the National Academy of Sciences of the United States of America. 1991 ; Vol. 88, No. 4. pp. 1217-1221.
@article{e0d52a3ec90549b9b7b10a5ec2dc8d77,
title = "Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation",
abstract = "One approach to gene therapy for hepatic diseases is to remove hepatocytes from an affected individual, genetically alter them in vitro, and reimplant them into a receptive locus. Although returning hepatocytes to the liver itself would be advantageous, the feasibility of this approach has never been evaluated due to the inability to distinguish donor from host hepatocytes. To unambiguously identify transplanted hepatocytes after transplantation, and to better quantitate their number and degree of liver function, two transgenic mouse lines were generated in a C57BL/6 background. The first expresses the Escherichia coli β-galactosidase gene from the relatively liver-specific human α1antitrypsin (hAAT) promoter and allows transgenic hepatocytes to be readily identified after 5-bromo-4-chloro-3-indolyl β-D-galactoside staining; the second produces the hAAT protein under control of the same promoter, which enables hepatocyte survival and maintenance of liver function to be quantitated by measuring the serum levels of hAAT. Hepatocytes isolated from transgenic donors were transplanted into nontransgenic C57BL/6 recipients by intrasplenic injection. Surprisingly, a large fraction of these cells were identified within the liver parenchyma but not the spleen at 2 months after transplantation. The high levels of serum hAAT detected in transplant recipients were stable for >6 months, suggesting that established cells will survive indefinitely. These results have important implications for liver organogenesis and hepatic gene therapy.",
keywords = "α-antitrypsin, β-galactosidase, Gene therapy, Hepatocyte transplantation",
author = "Ponder, {Katherine Parker} and Sanjeev Gupta and Frances Leland and Gretchen Darlington and Milton Finegold and Janet DeMayo and Ledley, {Fred D.} and Jayanta Roy-Chowdhury and Woo, {Savio L C}",
year = "1991",
language = "English (US)",
volume = "88",
pages = "1217--1221",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "4",

}

TY - JOUR

T1 - Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation

AU - Ponder, Katherine Parker

AU - Gupta, Sanjeev

AU - Leland, Frances

AU - Darlington, Gretchen

AU - Finegold, Milton

AU - DeMayo, Janet

AU - Ledley, Fred D.

AU - Roy-Chowdhury, Jayanta

AU - Woo, Savio L C

PY - 1991

Y1 - 1991

N2 - One approach to gene therapy for hepatic diseases is to remove hepatocytes from an affected individual, genetically alter them in vitro, and reimplant them into a receptive locus. Although returning hepatocytes to the liver itself would be advantageous, the feasibility of this approach has never been evaluated due to the inability to distinguish donor from host hepatocytes. To unambiguously identify transplanted hepatocytes after transplantation, and to better quantitate their number and degree of liver function, two transgenic mouse lines were generated in a C57BL/6 background. The first expresses the Escherichia coli β-galactosidase gene from the relatively liver-specific human α1antitrypsin (hAAT) promoter and allows transgenic hepatocytes to be readily identified after 5-bromo-4-chloro-3-indolyl β-D-galactoside staining; the second produces the hAAT protein under control of the same promoter, which enables hepatocyte survival and maintenance of liver function to be quantitated by measuring the serum levels of hAAT. Hepatocytes isolated from transgenic donors were transplanted into nontransgenic C57BL/6 recipients by intrasplenic injection. Surprisingly, a large fraction of these cells were identified within the liver parenchyma but not the spleen at 2 months after transplantation. The high levels of serum hAAT detected in transplant recipients were stable for >6 months, suggesting that established cells will survive indefinitely. These results have important implications for liver organogenesis and hepatic gene therapy.

AB - One approach to gene therapy for hepatic diseases is to remove hepatocytes from an affected individual, genetically alter them in vitro, and reimplant them into a receptive locus. Although returning hepatocytes to the liver itself would be advantageous, the feasibility of this approach has never been evaluated due to the inability to distinguish donor from host hepatocytes. To unambiguously identify transplanted hepatocytes after transplantation, and to better quantitate their number and degree of liver function, two transgenic mouse lines were generated in a C57BL/6 background. The first expresses the Escherichia coli β-galactosidase gene from the relatively liver-specific human α1antitrypsin (hAAT) promoter and allows transgenic hepatocytes to be readily identified after 5-bromo-4-chloro-3-indolyl β-D-galactoside staining; the second produces the hAAT protein under control of the same promoter, which enables hepatocyte survival and maintenance of liver function to be quantitated by measuring the serum levels of hAAT. Hepatocytes isolated from transgenic donors were transplanted into nontransgenic C57BL/6 recipients by intrasplenic injection. Surprisingly, a large fraction of these cells were identified within the liver parenchyma but not the spleen at 2 months after transplantation. The high levels of serum hAAT detected in transplant recipients were stable for >6 months, suggesting that established cells will survive indefinitely. These results have important implications for liver organogenesis and hepatic gene therapy.

KW - α-antitrypsin

KW - β-galactosidase

KW - Gene therapy

KW - Hepatocyte transplantation

UR - http://www.scopus.com/inward/record.url?scp=0026031297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026031297&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 1217

EP - 1221

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 4

ER -